Costs of predicting IDDM

Diabetologia

Volumn 41, Issue 1, 1998, Pages 79-85

  Hahl, J ^a,b,e   Simell, T ^b   Ilonen, J ^b   Knip, M ^c,d   Simell, O ^b  

^a UNIVERSITY OF TURKU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF OULU   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Autoimmunity; Costs; Genetic risk; Insulin dependent diabetes mellitus; Islet cell antibodies; Prediction; Prevention; Screening

Indexed keywords

HLA DQ ANTIGEN; INSULIN; PANCREAS ISLET CELL ANTIBODY; PLACEBO;

ADOLESCENT; ARTICLE; AUTOIMMUNITY; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOUBLE BLIND PROCEDURE; FINLAND; FOLLOW UP; GENE TARGETING; GENETIC COUNSELING; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HEALTH CARE COST; HUMAN; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEWBORN; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INTRANASAL; ADOLESCENT; AUTOANTIBODIES; CHILD; COSTS AND COST ANALYSIS; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FINLAND; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HLA-DQ ANTIGENS; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; INSULIN;

EID: 0031906364     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050870     Document Type: Article

References (38)

1. Bowman MA, Leiter EH, Atkinson MA (1994) Prevention of diabetes in the NOD mouse: implications for therapeutic intervention in human disease. Immunol Today 15: 115-120
2. Elias D, Cohen IR (1994) Peptide therapy for diabetes in NOD mice. Lancet 343: 704-706
3. Keller RJ, Eisenbarth GS, Jackson RA (1993) Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341: 1291
4. Lapinleimu H, Viikari J, Jokinen E et al. (1995) Prospective randomised trial in 1062 infants of diet low saturated fat and cholesterol. Lancet 345: 471-476
5. Niinikoski H, Viikari J, Rönnemaa T et al. (1996) Prospective randomized trial of low-saturated-fat, low-cholesterol diet during the first 3 years of life: The STRIP Baby Project. Circulation 94: 1386-1393
6. Becker D, Cakan N, LaPorte R, Drash A, Trucco M (1995) High risk DG alleles improve IDDM prediction in ICA + ve first degree relatives with decreased insulin secretion. Autoimmunity 21: 60 (Abstract)
7. Reijonen H, Ilonen J, Knip M, Åkerblom H (1991) HLA-DQB1 alleles and absence of Asp 57 as susceptibility factors of IDDM in Finland. Diabetes 40: 1640-1644
8. Karjalainen JK (1990) Islet cell antibodies as predictive markers for IDDM in children with high background incidence of disease. Diabetes 39: 1144-1150
9. Bazzigaluppi E, Pastore MR, Bonfanti R et al. (1995) GAD antibodies as a primary screening marker in first degree relatives of IDDM patients. Autoimmunity 21: 62 (Abstract)
10. Behme MT, Leushner J (1995) Predictive markers in first degree relatives of patients with insulin dependent diabetes mellilus. Autoimmunity 21: 62 (Abstract)
11. Karjalainen J, Vähäsalo P. Åkerblom HK, Knip M, and the DiMe-Study Group (1995) Predictive value of islet cell and insulin autoantibodies for IDDM in siblings less than 20 years of age is not associated with age at initial detection of autoantibodies. Autoimmunity 21: 65 (Abstract)
12. Kulmala P, Petersen JS, Vähäsalo P et al. (1995) Life-table analysis of progression to diabetes in siblings of children with IDDM in relation to IDDM associated autoantibodies. Autoimmunity 21: 61 (Abstract)
13. Leech NJ, McCulloch DK, Rowe RE, Palmer JP, Hagopian WA (1995) The role of GAD65AB in the prediction of IDDM in the general population and it's relationship to other susceptibility markers. Autoimmunity 21: 63 (Abstract)
14. Mackay IR, Byron SL, Rowley MJ, Whittingham SF, Zimmet PZ, Tuomilehto J (1995) Islet cell antibodies and anti-GAD as predictors of diabetes. Autoimmunity 21: 64 (Abstract)
15. Morales J, Puig-Domingo M, Vinets I, Ronningen KS, Dyrberg T, de Leiva A (1995) IDDM risk assesment of first degree relatives of a Spanish cohort by using a multiantibody screening programme combined with HLA markers. Autoimmunity 21: 61 (Abstract)
16. Verge CF, Gianani R, Yu L et al. (1995) Prediction of IDDM using a combination of insulin, glutamic acid decarboxylase and ICA512 autoantibodies. Autoimmunity 21: 59 (Abstract)
17. The DPT-1 Study Group (1995) The diabetes prevention trial - type 1 diabetes (DPT-1): Progress report. Autoimmunity 21: 66 (Abstract)
18. Reimers JI, Andersen HU Pociot F (1994) Nicotinamide and prevention of insulin-dependent diabetes mellitus. Rationale, effects, toxicology and clinical experiences. ENDIT Group. Ugeskr Laeger 156: 461-465
19. Sjöroos M, Iitiä A, Ilonen J, Reijonen H, Lövgren T (1995) Triple-label hybridization assay for type-1 diabetes-related HLA alleles. Biotechniques 18: 870-877
20. Kangas T (1995) The FINNDIAB report. Health care of people with diabetes in Finland. Research Reports 58. Stakes, Saarijärvi
21. Simell TT, Sintonen H, Hahl J, Simell OG (1996) Costs of insulin-dependent diabetes mellitus. PharmacoEconomics 9: 24-38
22. Schiffrin A, Ciampi A, Hendricks L, Rozen R, Weitzner G (1994) Evidence for different clinical subtypes of type 1 diabetes mellitus: a prospective study. Diabetes Res Clin Pract 23:95-102
23. Schiffrin A, Colle E, Ciampi A, Hendricks L, Poussier P (1993) Different rates of conversion to IDDM in siblings of type 1 diabetic children: the Montreal family study. Diabetes Res Clin Pract 21: 1-3
24. Bonifacio E, Genovese S, Braghi S et al. (1995) Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia 38: 816-822
25. Bingley PJ, Christie MR, Bonifacio E et al. (1994) Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 43: 1304-1310
26. Mustonen A, Knip M, Huttunen NP, Puukka R, Käär M, Åkerblom HK (1984) Evidence of delayed beta-cell destruction in type 1 (insulin dependent) diabetic patients with persisting complement-fixing cytoplasmic islet cell antibodies. Diabetologia 27: 421-426
27. Drummond MF (1980) Principles of economic appraisal in health care. Oxford University Press, Oxford
28. Robinson R (1993) Economic evaluation and health care. Costs and cost-minimisation analysis. BMJ 307: 726-728
29. Luce RB, Elixhauser A (1990) Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 6: 57-75
30. Weinstein MC (1990) Principles of cost-effective resource allocation in health care organizations. Int J Technol Assess Health Care 6: 93-103
31. Whynes DK, Walker AR (1995) On approximations in treatment costing. Health Econ 4: 31-39
32. Koopmanschap MA, Rutten FFH (1994) The impact of indirect costs on outcomes of health care programs. Health Econ 3: 385-393
33. Drummond MF, Stoddart GL, Torrance GW (1987) Methods for the economic evaluation of health care programmes. Oxford University Press, Oxford
34. Official Statistics of Finland (1994) Wage statistics 1993/1994. Wages. Statistics Center of Finland, Helsinki
35. Department of Health and Human Services (1995) Disease-specific estimates of direct and indirect costs of illness and NIH support. Public Health Service. National Institutes of Health. Office of the Director
36. Bingley PJ, Colman P Eisenbarth GS et al. (1992) Standardization of IVGTT to predict IDDM. Diabetes Care 15: 1313-1316
37. Schuler GD, Boguski MS, Stewart EA et al. (1996) A gene map of the human genome. Science 274: 540
38. Marshall E, Pennisi E (1996) NIH launches the final push to sequence the genome. Science 272: 188-189